VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
VTAE was delisted on the 24th of October, 2016.
15 hedge funds and large institutions have $45M invested in VITAE PHARMACEUTICALS INC COMMON STOCK in 2014 Q3 according to their latest regulatory filings, with 15 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$20.3M |
| 2 |
AWMDMG
Austin W. Marxe & David M. Greenhouse
New York
|
+$6.41M |
| 3 |
BI
BVF Inc
San Francisco,
California
|
+$5.18M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$4.76M |
| 5 |
WT
Wellcome Trust
London,
United Kingdom
|
+$4.04M |
Top Sellers
VTAE Hedge Fund Activity: Q3 2014 in Review
15 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) for Q3 2014, worth a combined $45M.
Buyers outnumbered sellers: 15 funds opened new VTAE positions and 0 closed out — a net gain of 15 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was NEA Management Company, opening a new position worth an estimated $20.3M.
- 15 institutional investors held VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $45M of VITAE PHARMACEUTICALS INC COMMON STOCK stock for Q3 2014.
- 15 funds opened new VITAE PHARMACEUTICALS INC COMMON STOCK positions in Q3 2014 and 0 closed out, a net change of +15 holders.
- The largest VITAE PHARMACEUTICALS INC COMMON STOCK buyer in Q3 2014 was NEA Management Company, an estimated $20.3M added.
Based on aggregated 13F filings for Q3 2014.